Covered recipient · General Payments record
JORGE TOMAS CASO
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$11.57
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $11.57 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $11.57 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JORGE TOMAS CASO
NPI 1457308157 · CMS profile ID 201338
Allopathic & Osteopathic Physicians / Family Medicine
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $11.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $11.57 | 09/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738478165 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,513,175.40 | 309 |
| PY2024 | Recipient | $2,105.91 | 13 |
| PY2024 | Principal investigator | $5,484,672.89 | 220 |
| PY2023 | Recipient | $1,815.05 | 10 |
| PY2023 | Principal investigator | $6,619,562.71 | 1,445 |
| PY2022 | Principal investigator | $4,761,350.73 | 1,335 |
| PY2021 | Principal investigator | $244,385.00 | 24 |
| PY2019 | Principal investigator | $19,780.00 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
233 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ModernaTX, Inc. | $75.13 | 12/30/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147131029 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 12/30/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147131049 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $16,000.00 | 12/27/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699302 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 12/27/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699304 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,000.00 | 12/27/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699306 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,000.00 | 12/27/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699308 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $50.00 | 12/27/2024 | Non-covered Recipient Entity Suncoast Research Associates, Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128702148 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $660.00 | 12/27/2024 | Non-covered Recipient Entity Suncoast Research Associates, Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128702150 |
| Principal investigator 1 | ModernaTX, Inc. | $249.45 | 12/26/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147131027 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 12/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147131047 |
| Principal investigator 1 | ModernaTX, Inc. | $76,763.34 | 12/23/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147131033 |
| Principal investigator 1 | ModernaTX, Inc. | $19,675.34 | 12/23/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147131037 |
| Principal investigator 1 | ModernaTX, Inc. | $412,081.03 | 12/19/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147131031 |
| Principal investigator 1 | ModernaTX, Inc. | $138,381.16 | 12/19/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147131035 |
| Principal investigator 1 | ModernaTX, Inc. | $25,781.08 | 12/19/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147131053 |
| Principal investigator 1 | Bavarian Nordic A/S | $200.00 | 12/18/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663254 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,452.00 | 12/16/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078956993 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,933.27 | 12/13/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663246 |
| Principal investigator 1 | Janssen Research & Development, LLC | $620.00 | 12/11/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957133 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 12/11/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147131025 |
| Principal investigator 1 | ModernaTX, Inc. | $335.18 | 12/06/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130823 |
| Principal investigator 1 | ModernaTX, Inc. | $236.25 | 12/06/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130825 |
| Principal investigator 1 | ModernaTX, Inc. | $32,504.59 | 12/06/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130827 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,031.70 | 12/02/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699258 |
| Principal investigator 1 | ModernaTX, Inc. | $671,690.40 | 11/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147131001 |
| Principal investigator 1 | Novavax Inc | $2,323.68 | 11/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123376815 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $33,189.89 | 11/22/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699262 |
| Principal investigator 1 | ModernaTX, Inc. | $1,289.21 | 11/21/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147131005 |
| Principal investigator 1 | ModernaTX, Inc. | $7,724.12 | 11/21/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147131011 |
| Principal investigator 1 | Novavax Inc | $120.00 | 11/21/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123375661 |
| Principal investigator 1 | Novavax Inc | $225.00 | 11/21/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123375663 |
| Principal investigator 1 | Bavarian Nordic A/S | $28,007.50 | 11/20/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663244 |
| Principal investigator 1 | Janssen Research & Development, LLC | $978.00 | 11/20/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957017 |
| Principal investigator 1 | ModernaTX, Inc. | $23,193.30 | 11/20/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130821 |
| Principal investigator 1 | Novavax Inc | $10,950.00 | 11/14/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123377905 |
| Principal investigator 1 | ModernaTX, Inc. | $75.13 | 11/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147130995 |
| Principal investigator 1 | ModernaTX, Inc. | $12,000.00 | 11/08/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130997 |
| Principal investigator 1 | Novavax Inc | $1,300.00 | 11/07/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123375141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,372.00 | 11/06/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957471 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 11/06/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147131009 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $19,999.31 | 11/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1095480844 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $22,490.30 | 11/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1095481478 |
| Principal investigator 1 | ModernaTX, Inc. | $204.00 | 10/31/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130975 |
| Principal investigator 1 | ModernaTX, Inc. | $102.45 | 10/29/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147130977 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,200.00 | 10/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663252 |
| Principal investigator 1 | ModernaTX, Inc. | $3,121.00 | 10/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130789 |
| Principal investigator 1 | ModernaTX, Inc. | $2,495.00 | 10/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130791 |
| Principal investigator 1 | ModernaTX, Inc. | $1,796.00 | 10/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130793 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 10/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130795 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,931.24 | 10/25/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699264 |
| Recipient | SANOFI PASTEUR INC. | $77.00 | 10/24/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698398 |
| Recipient | SANOFI PASTEUR INC. | $81.00 | 10/24/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698400 |
| Recipient | SANOFI PASTEUR INC. | $55.00 | 10/24/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698402 |
| Recipient | SANOFI PASTEUR INC. | $55.00 | 10/24/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698404 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,180.70 | 10/23/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663248 |
| Principal investigator 1 | Bavarian Nordic A/S | $400.20 | 10/23/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663250 |
| Principal investigator 1 | Bavarian Nordic A/S | $43,064.04 | 10/23/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663256 |
| Principal investigator 1 | Janssen Research & Development, LLC | $634.00 | 10/23/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957433 |
| Recipient | SANOFI PASTEUR INC. | $75.00 | 10/23/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698388 |
| Recipient | SANOFI PASTEUR INC. | $55.00 | 10/23/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698390 |
| Recipient | SANOFI PASTEUR INC. | $85.00 | 10/23/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698392 |
| Recipient | SANOFI PASTEUR INC. | $55.00 | 10/23/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698394 |
| Recipient | SANOFI PASTEUR INC. | $203.00 | 10/23/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698396 |
| Recipient | SANOFI PASTEUR INC. | $375.55 | 10/22/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698380 |
| Recipient | SANOFI PASTEUR INC. | $677.82 | 10/22/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698382 |
| Recipient | SANOFI PASTEUR INC. | $108.54 | 10/22/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698384 |
| Recipient | SANOFI PASTEUR INC. | $203.00 | 10/22/2024 | Covered Recipient Physician | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128698386 |
| Principal investigator 1 | ModernaTX, Inc. | $25,359.53 | 10/16/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130813 |
| Principal investigator 1 | ModernaTX, Inc. | $49.89 | 10/16/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130973 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $28,772.10 | 10/11/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699260 |
| Principal investigator 1 | ModernaTX, Inc. | $1,210.40 | 10/03/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147130981 |
| Principal investigator 1 | ModernaTX, Inc. | $1,120.50 | 10/02/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130785 |
| Principal investigator 1 | ModernaTX, Inc. | $775.00 | 10/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130787 |
| Principal investigator 1 | ModernaTX, Inc. | $414.00 | 10/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130815 |
| Principal investigator 1 | Janssen Research & Development, LLC | $845.00 | 09/25/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957169 |
| Principal investigator 1 | ModernaTX, Inc. | $45,818.19 | 09/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130959 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,012.00 | 09/18/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078956829 |
| Principal investigator 1 | ModernaTX, Inc. | $2,341.50 | 09/18/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130777 |
| Principal investigator 1 | ModernaTX, Inc. | $399.12 | 09/16/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147130953 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 09/12/2024 | Non-covered Recipient Entity JBR CLINICAL RESEARCH | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147192184 |
| Principal investigator 1 | ModernaTX, Inc. | $2,607.12 | 09/06/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147130963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,750.00 | 09/04/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078956977 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 09/04/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130773 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 09/04/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130775 |
| Principal investigator 1 | ModernaTX, Inc. | $285,480.42 | 09/02/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130955 |
| Principal investigator 1 | ModernaTX, Inc. | $2,070.00 | 08/28/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130769 |
| Principal investigator 1 | Bavarian Nordic A/S | $600.00 | 08/23/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663242 |
| Principal investigator 1 | ModernaTX, Inc. | $598.68 | 08/20/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130937 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $234.60 | 08/19/2024 | Non-covered Recipient Entity Suncoast Research Associates LLC | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1121160382 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,728.00 | 08/19/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957067 |
| Principal investigator 1 | ModernaTX, Inc. | $23,415.03 | 08/16/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130765 |
| Principal investigator 1 | ModernaTX, Inc. | $414.00 | 08/16/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130767 |
| Principal investigator 1 | ModernaTX, Inc. | $3,450.07 | 08/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147130941 |
| Principal investigator 1 | ModernaTX, Inc. | $43,746.00 | 08/08/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147130939 |
| Principal investigator 1 | ModernaTX, Inc. | $45,117.05 | 08/07/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130763 |
| Principal investigator 1 | ModernaTX, Inc. | $49,289.88 | 08/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,956.00 | 07/26/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078956773 |
| Principal investigator 1 | Novavax Inc | $750.00 | 07/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123375659 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,000.00 | 07/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663236 |
| Principal investigator 1 | Bavarian Nordic A/S | $700.00 | 07/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663238 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,200.00 | 07/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663240 |
| Principal investigator 1 | ModernaTX, Inc. | $3,122.00 | 07/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130761 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 07/15/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130841 |
| Principal investigator 1 | ModernaTX, Inc. | $25,756.53 | 07/03/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130759 |
| Principal investigator 1 | ModernaTX, Inc. | $7,352.64 | 06/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130919 |
| Principal investigator 1 | ModernaTX, Inc. | $24,610.84 | 06/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147130929 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,562.41 | 06/26/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663216 |
| Principal investigator 1 | Janssen Research & Development, LLC | $978.00 | 06/25/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957595 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,932.00 | 06/21/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699168 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,363.94 | 06/21/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699180 |
| Principal investigator 1 | Novavax Inc | $10,434.08 | 06/20/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123376239 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $519,639.28 | 06/20/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699166 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $228,131.49 | 06/20/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699174 |
| Principal investigator 1 | ModernaTX, Inc. | $105,504.00 | 06/19/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130917 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $20,977.35 | 06/19/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699164 |
| Principal investigator 1 | ModernaTX, Inc. | $23,805.80 | 06/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130925 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,956.00 | 06/14/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957011 |
| Principal investigator 1 | ModernaTX, Inc. | $12,762.90 | 06/13/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130915 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130913 |
| Principal investigator 1 | ModernaTX, Inc. | $775.00 | 06/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130921 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,242.00 | 06/10/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699176 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $694.14 | 06/10/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699178 |
| Principal investigator 1 | ModernaTX, Inc. | $1,250.00 | 06/05/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130911 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $175.00 | 06/04/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699170 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,150.00 | 06/04/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699172 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,250.00 | 06/04/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699182 |
| Principal investigator 1 | ModernaTX, Inc. | $15,700.00 | 06/03/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130909 |
| Principal investigator 1 | ModernaTX, Inc. | $100.50 | 05/31/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130893 |
| Principal investigator 1 | Bavarian Nordic A/S | $16,138.44 | 05/29/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663214 |
| Principal investigator 1 | ModernaTX, Inc. | $19,441.00 | 05/29/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130897 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $146,410.77 | 05/28/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699152 |
| Principal investigator 1 | ModernaTX, Inc. | $4,870.00 | 05/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130899 |
| Principal investigator 1 | ModernaTX, Inc. | $57,794.36 | 05/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,372.00 | 05/22/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957665 |
| Principal investigator 1 | ModernaTX, Inc. | $7,295.66 | 05/22/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130751 |
| Principal investigator 1 | ModernaTX, Inc. | $3,222.75 | 05/22/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130753 |
| Principal investigator 1 | ModernaTX, Inc. | $441.60 | 05/22/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130755 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 05/14/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147130905 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,959.22 | 05/13/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699156 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,500.00 | 05/13/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699188 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $20,000.00 | 05/13/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699192 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $273.24 | 05/08/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699186 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $593.40 | 05/08/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699190 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 05/06/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699138 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $100.00 | 05/06/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699148 |
| Principal investigator 1 | ModernaTX, Inc. | $20,085.26 | 05/03/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130895 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $393,144.99 | 05/03/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699184 |
| Principal investigator 1 | Novavax Inc | $5,174.40 | 05/02/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123374611 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699120 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,450.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699126 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,563.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699128 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699130 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $900.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699132 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,000.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699134 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,500.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699136 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,900.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699142 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699144 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $15,000.00 | 04/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699150 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,928.00 | 04/26/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957171 |
| Principal investigator 1 | ModernaTX, Inc. | $6,695.00 | 04/25/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A RANDOMIZED, OBSERVER-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY TO INVESTIGATE THE SAFETY, IMMUNOGENICITY, AND RELATIVE VACCINE EFFICACY OF MRNA-1283.222 ADMINISTERED AS A BOOSTER DOSE COMPARED WITH MRNA-1273.222 IN PARTICIPANTS AGED 12 YEARS AND OLDER FOR THE PREVENTION OF COVID-19 | No dispute reported | 06/30/2026 | 1147151469 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $45,073.96 | 04/25/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699154 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,050.00 | 04/25/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699158 |
| Principal investigator 1 | ModernaTX, Inc. | $13,165.00 | 04/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130735 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 04/22/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130889 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $15,555.41 | 04/19/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699122 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,563.00 | 04/19/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699124 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,450.00 | 04/19/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128699140 |
| Principal investigator 1 | Bavarian Nordic A/S | $11,973.80 | 04/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663218 |
| Principal investigator 1 | ModernaTX, Inc. | $1,179.00 | 04/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130739 |
| Principal investigator 1 | ModernaTX, Inc. | $1,080.00 | 04/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130741 |
| Principal investigator 1 | ModernaTX, Inc. | $625.00 | 04/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130743 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 04/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130745 |
| Principal investigator 1 | ModernaTX, Inc. | $4,880.00 | 04/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130747 |
| Principal investigator 1 | Novavax Inc | $10,500.00 | 04/11/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123374070 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,979.61 | 04/11/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699160 |
| Principal investigator 1 | ModernaTX, Inc. | $45,940.18 | 04/10/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130737 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 04/10/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699146 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $7,500.00 | 04/10/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699162 |
| Principal investigator 1 | Bavarian Nordic A/S | $950.00 | 04/05/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663220 |
| Principal investigator 1 | ModernaTX, Inc. | $5,500.00 | 03/28/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147130873 |
| Principal investigator 1 | ModernaTX, Inc. | $47,402.05 | 03/28/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130881 |
| Principal investigator 1 | Bavarian Nordic A/S | $76,449.75 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663132 |
| Principal investigator 1 | Bavarian Nordic A/S | $15,442.20 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663144 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,993.20 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663146 |
| Principal investigator 1 | Bavarian Nordic A/S | $500.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663160 |
| Principal investigator 1 | Bavarian Nordic A/S | $700.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663162 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,000.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663164 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,000.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663166 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,257.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663168 |
| Principal investigator 1 | ModernaTX, Inc. | $2,070.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130721 |
| Principal investigator 1 | ModernaTX, Inc. | $414.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130723 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 03/27/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130725 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,067.00 | 03/25/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957591 |
| Principal investigator 1 | ModernaTX, Inc. | $28,608.07 | 03/21/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130871 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,400.00 | 03/14/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699104 |
| Principal investigator 1 | ModernaTX, Inc. | $49,952.06 | 03/13/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130719 |
| Principal investigator 1 | ModernaTX, Inc. | $31,434.40 | 03/13/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130869 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,500.00 | 03/11/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699102 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $9,450.00 | 03/11/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699106 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $15,000.00 | 03/11/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699108 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,260.00 | 03/05/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699096 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $15,000.00 | 03/05/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699098 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,411.00 | 03/04/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957515 |
| Principal investigator 1 | ModernaTX, Inc. | $900.00 | 03/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130875 |
| Principal investigator 1 | ModernaTX, Inc. | $1,769.85 | 02/28/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130851 |
| Principal investigator 1 | ModernaTX, Inc. | $25,788.59 | 02/26/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147130861 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $16,782.50 | 02/24/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | No dispute reported | 06/30/2026 | 1095480842 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 02/22/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147130853 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $522.48 | 02/21/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR | No dispute reported | 06/30/2026 | 1127543825 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,500.00 | 02/21/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078957317 |
| Principal investigator 1 | ModernaTX, Inc. | $8,585.51 | 02/21/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130709 |
| Principal investigator 1 | Novavax Inc | $5,000.00 | 02/15/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123377903 |
| Principal investigator 1 | ModernaTX, Inc. | $7,250.00 | 02/14/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130707 |
| Principal investigator 1 | ModernaTX, Inc. | $3,100.00 | 02/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130855 |
| Principal investigator 1 | Novavax Inc | $15,320.48 | 02/08/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1123375139 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,350.00 | 02/08/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128699110 |
| Principal investigator 1 | ModernaTX, Inc. | $29,308.79 | 02/02/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130715 |
| Principal investigator 1 | ModernaTX, Inc. | $176,321.43 | 02/02/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147130717 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,650.00 | 02/02/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699114 |
| Principal investigator 1 | Bavarian Nordic A/S | $32,113.80 | 02/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663136 |
| Principal investigator 1 | Bavarian Nordic A/S | $892.05 | 02/01/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination | No dispute reported | 06/30/2026 | 1119663138 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,257.62 | 01/31/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699112 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $300.00 | 01/31/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128699116 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,420.00 | 01/29/2024 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1128699100 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,446.00 | 01/26/2024 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 1078956929 |
| Principal investigator 1 | ModernaTX, Inc. | $55,669.51 | 01/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130699 |
| Principal investigator 1 | ModernaTX, Inc. | $1,340.00 | 01/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147130701 |
| Principal investigator 1 | ModernaTX, Inc. | $439,421.95 | 01/17/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1147130839 |
| Principal investigator 1 | ModernaTX, Inc. | $80,429.28 | 01/16/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147130835 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,000.00 | 01/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663154 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,500.00 | 01/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663156 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,000.00 | 01/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1119663158 |
| Principal investigator 1 | ModernaTX, Inc. | $1,400.00 | 01/12/2024 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP LLC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147130833 |